公开(公告)号：EP2647707A4

公开(公告)日：2014-04-30

申请号：EP11845786

申请日：2011-11-30

申请人： CHUGAI PHARMACEUTICAL CO LTD

发明人： NEZU JUNICHI ,  ISHIGURO TAKAHIRO ,  NARITA ATSUSHI ,  SAKAMOTO AKIHISA ,  KAWAI YUMIKO ,  IGAWA TOMOYUKI ,  KURAMOCHI TAICHI

IPC分类号： C12N15/09 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  C07K16/46 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10

CPC分类号： C07K16/46 ,  A61K2039/505 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/303 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30

摘要： By replacing the antigen-binding domain, the present inventors discovered novel polypeptide complexes that retain BiTE's strong anti-tumor activity and excellent safety properties, as well as have long half-life in blood and can damage various different target cells.

公开(公告)号：EP3199628A4

公开(公告)日：2018-06-06

申请号：EP15844692

申请日：2015-09-25

申请人： CHUGAI PHARMACEUTICAL CO LTD

发明人： NEZU JUNICHI ,  NARITA ATSUSHI ,  ISHIGURO TAKAHIRO ,  SAKURAI MIKA ,  SHIRAIWA HIROTAKE ,  HIRONIWA NAOKA ,  IGAWA TOMOYUKI ,  KAWAI YUMIKO

IPC分类号： C07K16/30 ,  A61K39/395 ,  C07K16/28

CPC分类号： C07K16/468 ,  A61K39/395 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/303 ,  C07K16/46 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94 ,  C12N5/10 ,  C12N15/09

摘要： Novel multispecific antigen-binding molecules maintaining excellent cellular cytotoxicity and high stability, which comprise a domain that contains an antibody variable region having glypican 3-binding activity and a domain that contains an antibody variable region having T-cell receptor complex-binding activity, were discovered. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing glypican 3, it is possible to produce novel pharmaceutical compositions for treating or preventing various cancers.

公开(公告)号：EP2762493A4

公开(公告)日：2015-06-03

申请号：EP12837276

申请日：2012-09-28

申请人： CHUGAI PHARMACEUTICAL CO LTD

发明人： IGAWA TOMOYUKI ,  MAEDA ATSUHIKO ,  TAMBA SHIGERO ,  KITAZAWA TAKEHISA ,  BABA TAKESHI ,  RUIKE YOSHINAO ,  NEZU JUNICHI

IPC分类号： C07K16/18 ,  A61K39/00 ,  A61K39/395 ,  A61P31/04 ,  C07K16/00 ,  C07K16/24 ,  C07K16/28 ,  C07K16/46 ,  C12N15/09 ,  C12P21/08

CPC分类号： C07K16/24 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/18 ,  C07K16/22 ,  C07K16/248 ,  C07K16/2866 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/64 ,  C07K2317/70 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

公开(公告)号：EP0816501A4

公开(公告)日：2000-04-26

申请号：EP96906032

申请日：1996-03-15

申请人： CHUGAI PHARMACEUTICAL CO LTD

发明人： NEZU JUNICHI

IPC分类号： C12N1/21 ,  C12N9/12 ,  C12N15/12 ,  C12N15/54 ,  C12N9/10

CPC分类号： C12N9/1205

摘要： Cloning of a cDNA of a novel protein kinase which is assumed to play various roles in vivo. A DNA containing a base sequence which encodes an amino acid sequence encoding a novel protein kinase, a base sequence which is the same as the above-mentioned one except having partial insertion, deletion or replacement, or a base sequence hybridizable therewith; a plasmid having this DNA; a transformant having this plasmid; a process for producing the DNA; and an oligonucleotide hybridizable specifically with the base sequence encoding the above-mentioned amino acid sequence.

公开(公告)号：EP2647706A4

公开(公告)日：2015-04-22

申请号：EP11845709

申请日：2011-11-30

申请人： CHUGAI PHARMACEUTICAL CO LTD

发明人： IGAWA TOMOYUKI ,  ISHII SHINYA ,  FUNAKI MIHO ,  HIRONIWA NAOKA ,  MAEDA ATSUHIKO ,  NEZU JUNICHI ,  RUIKE YOSHINAO ,  BABA TAKESHI ,  SHIMIZU SHUN

IPC分类号： C12N15/09 ,  A61K39/395 ,  C07K16/18 ,  C07K16/46 ,  C12P21/08 ,  G01N33/15 ,  G01N33/50

CPC分类号： C07K16/18 ,  C07K16/248 ,  C07K16/2866 ,  C07K16/4291 ,  C07K2317/565 ,  G01N33/53

摘要： An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times of antigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for improving the plasma retention of an antigen-binding molecule, as well as antigen-binding molecules that allow enhanced antigen uptake into cells, antigen-binding molecules having an increased number of times of antigen binding, antigen-binding molecules that can promote reduction of the antigen concentration in plasma when administered, antigen-binding molecules with improved plasma retention, pharmaceutical compositions comprising the above antigen-binding molecules, and methods for producing them. The present inventors revealed that the above objective can be achieved by using antigen-binding molecules that show calcium-dependent antigen-antibody reaction.